Author: Healio ophthalmology

VIDEO: Subretinal fluid seen as ‘protective’ against development of macular atrophy

LAS VEGAS — At the American Academy of Ophthalmology annual meeting, Brandon G. Busbee, MD, reports on risk factors associated with development of macular atrophy as determined by 2-year ad hoc findings from the HARBOR trial, in which the presence of subretinal fluid in the baseline population “seemed to be protective” against development of macular atrophy.

Single dose of bimatoprost ocular insert demonstrates IOP reduction in glaucoma, ocular hypertension

LAS VEGAS — A single dose of a novel topical bimatoprost ocular insert demonstrated sustained IOP reduction in patients with glaucoma and ocular hypertension at 6 months, according to phase 2 study results presented here. “Despite highly effective topical treatments, half of our patients stop using their drops by 1 year, and among those who do continue to use their drops, many of them have difficulty using them properly. … There is a pressing need for sustained patient behavior independent delivery of glaucoma medications to prevent blindness,” James D. Brandt, (Read more...)

AAO launches effort to rebrand itself as vanguard of eye care

The American Academy of Ophthalmology is embarking on an initiative to rebrand itself and foster an understanding of the specialty’s impact on society, a speaker said at the AAO annual meeting in Las Vegas.AAO CEO David W. Parke II, MD, described the rebranding effort during a press briefing. Although the initiative will involve changes to the AAO’s logo, tagline, design of products and website, it is mainly designed to enhance the public’s understanding of the goals and contributions of ophthalmology, Parke said.

AGTC receives orphan drug designation for gene therapy to treat achromatopsia

The FDA has granted orphan drug designation to AGTC’s gene therapy product candidate for the treatment of achromatopsia caused by mutations in the CNGA3 gene, AGTC announced in a press release. “Receiving U.S. orphan drug designation is another significant milestone as we continue to advance our pipeline of novel gene therapies to treat rare inherited eye disorders,” Sue Washer, president and CEO of AGTC, said in the release.

Intravitreal sirolimus resolves vitreous haze in SAKURA study 1

LAS VEGAS — Intravitreal sirolimus may significantly resolve vitreous haze in patients with no anterior segment involvement, according to a presentation here. Pravin U. Dugel, MD, presented double-masked data of vitreous haze scores and steroid tapering success results of 347 patients with noninfectious uveitis of the posterior segment from month 5 of the SAKURA study 1 post hoc analysis at the American Academy of Ophthalmology annual meeting.

OCT improves diagnosis, monitoring of neuro-ophthalmic diseases

LAS VEGAS — OCT is increasingly useful in diagnosing disorders that affect optical pathways to the brain, a speaker told colleagues.“[OCT technology] is really affecting the way that we approach patients and diagnose their problems. Some of them can be life-threatening in neuro-ophthalmology,” Randy H. Kardon, MD, PhD, said during a press briefing on “Innovations in vision: Nanotech, nearsightedness and neuro-ophthalmology imaging.”

Pfizer, Allergan to combine in $160 billion deal

Pfizer and Allergan announced today that their boards of directors have approved a definitive merger agreement in which Pfizer will combine with Allergan.The merger has a stock transaction currently valued at $363.63 per Allergan share, for a total value of approximately $160 billion, based on the closing price of Pfizer common stock of $32.18 on Nov. 20, according to a press release from both companies. Under the proposal, the businesses of Pfizer and Allergan will be combined under Allergan plc, which will be renamed Pfizer plc.

Amniotic membrane transplantation may prevent ocular sequelae in Stevens-Johnson syndrome

LAS VEGAS — Ocular sequelae from Stevens-Johnson syndrome may be prevented with amniotic membrane transplantation when applied within the first 6 days after symptom onset, according to a paper presentation here. “Medical management is appropriate for patients who have more mild ocular manifestations, and this often includes various combinations of antibiotics, topical steroids, as well as cyclosporine and lubrication,” Amy Marie Cherof, MD, said at the American Academy of Ophthalmology annual meeting. “In addition, amniotic membrane transplantation has been shown in many studies, including those of our own, to decrease (Read more...)